MAP2K7 and melanoma: Another ongoing study is exploring the efficacy of BKM120 (buparlisib—PI3K inhibitor) in combination with LGX818/MEK162 (BRAF inhibitor/MEK inhibitor) in treating BRAF V600 melanoma.